Small cell lung cancer

Survival

Survival after definitive treatment of SCLC is dependent on stage. The 5-year survival rates are approximately 30% to 35% for limited stage and 1% to 5% for extensive stage.[56]Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017 Aug;18(8):1116-25. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555437 http://www.ncbi.nlm.nih.gov/pubmed/28642008?tool=bestpractice.com [62]Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220-9. https://www.nejm.org/doi/10.1056/NEJMoa1809064 http://www.ncbi.nlm.nih.gov/pubmed/30280641?tool=bestpractice.com Treatment patterns and short survival outcomes for SCLC have remained constant from the year 2000 to 2020. However, this may change after the adoption of immuno-oncology therapies for SCLC.[84]Johal S, Hettle R, Carroll J, et al. Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review. J Thorac Dis. 2021 Jun;13(6):3692-707. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264706 http://www.ncbi.nlm.nih.gov/pubmed/34277061?tool=bestpractice.com ​​